Children with resistant leukemia given CRISPR-edited T cells: Phase 1 study results reported
Researchers have used CRISPR/Cas9 technology to engineer donor T cells to try to treat seriously ill children with resistant leukemia, who had otherwise exhausted all available therapies.
Materials provided by University College London. Note: Content may be edited for style and length.
Source link aaaaa